When the immune system becomes the cause of inflammation

Autoimmune liver diseases: why the body attacks its own organ

Autoimmune liver diseases are a group of chronic conditions in which organ damage is not caused by a virus, alcohol or excess fat, but by impaired immune system function. Normally, immunity protects the body from infections and foreign factors. In autoimmune processes, this system mistakenly recognizes its own cells or structures as dangerous and triggers an inflammatory reaction against them.

The liver is especially important from an immunological perspective. It constantly interacts with substances arriving from the intestine through the portal vein, participates in detoxification, processes metabolic products and works with a large number of immune cells. Therefore, disruption of immune regulation can lead to different forms of liver damage: inflammation of hepatocytes, injury to small bile ducts or chronic inflammation of larger bile ducts.

The main autoimmune and immune-mediated liver diseases usually include autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis. These conditions differ in their mechanism of damage, laboratory pattern, clinical course and treatment approaches. But they share one feature: without timely diagnosis, chronic inflammation may gradually lead to fibrosis, cirrhosis and complications.

Autoimmune hepatitis: inflammation of liver cells

Autoimmune hepatitis is a chronic inflammatory disease in which the immune system attacks liver cells. It can develop at different ages and occurs in both women and men, although it is diagnosed more often in women. The disease may begin gradually, with nonspecific symptoms, or present acutely, with a marked increase in liver enzymes and signs of hepatitis.

The main feature of autoimmune hepatitis is active inflammation of liver tissue. Blood tests often show elevated ALT and AST, sometimes markedly increased. Elevated immunoglobulins, especially IgG, and autoantibodies may also be detected. However, the diagnosis is not made based on a single test. The physician evaluates the clinical picture, laboratory markers and excludes viral hepatitis, drug-induced liver injury, fatty liver disease and other causes of inflammation.

Symptoms of autoimmune hepatitis may vary. In some patients, the disease is detected accidentally because of elevated liver enzymes. Others complain of fatigue, weakness, reduced appetite, discomfort in the right upper abdomen, joint pain, skin manifestations or jaundice. Sometimes the disease develops rapidly and resembles acute viral hepatitis. In more advanced cases, the first manifestation may already be cirrhosis or its complications.

Treatment of autoimmune hepatitis is usually aimed at suppressing excessive immune activity. Anti-inflammatory and immunomodulatory drugs are used for this purpose. The goal of therapy is to reduce inflammation, normalize liver enzymes, decrease immunological activity and prevent fibrosis formation. With a good response to treatment, the disease can be controlled for a long time, but therapy requires regular follow-up and careful adjustment.

Primary biliary cholangitis: damage to small bile ducts

Primary biliary cholangitis is a chronic autoimmune disease in which the small intrahepatic bile ducts are mainly affected. Bile ducts are necessary for carrying bile out of the liver. If they are gradually damaged and destroyed, bile flow worsens, cholestasis develops, and liver tissue is exposed to chronic irritation and inflammation.

This disease often develops slowly. In the early stages, a person may have no pronounced complaints, and changes are detected through blood tests. A typical laboratory sign is an increase in alkaline phosphatase and GGT, markers associated with cholestasis. Antimitochondrial antibodies are also often detected. But, as with other liver diseases, diagnosis requires comparison of laboratory results, symptoms, imaging findings and exclusion of other causes of impaired bile flow.

One characteristic symptom of primary biliary cholangitis may be itching. It sometimes appears before pronounced signs of impaired liver function. Fatigue, dry skin and mucous membranes, discomfort in the right upper abdomen, elevated cholesterol and deficiency of fat-soluble vitamins during long-term cholestasis are also possible. In later stages, the disease may lead to fibrosis, cirrhosis and portal hypertension.

Treatment of primary biliary cholangitis is directed at improving bile flow, reducing bile duct injury and slowing disease progression. Drugs that influence bile acids and cholestasis are used for this purpose. An important part of management is monitoring biochemical markers, assessing response to therapy, observing fibrosis, correcting deficiencies and treating symptoms, especially itching.

Primary sclerosing cholangitis: chronic inflammation of bile ducts

Primary sclerosing cholangitis is a chronic disease in which inflammation and scarring affect the bile ducts. Unlike primary biliary cholangitis, both intrahepatic and extrahepatic bile ducts may be involved. Gradually, strictures form, bile flow is impaired, and the risk of inflammatory complications, fibrosis and cirrhosis increases.

This disease is often associated with inflammatory bowel disease, especially ulcerative colitis. This association is important because the patient may need follow-up not only by a hepatologist, but also by a gastroenterologist. Primary sclerosing cholangitis may remain asymptomatic for a long time, or it may present with fatigue, itching, episodes of jaundice, fever during bile duct inflammation, pain or abdominal discomfort.

Laboratory signs of cholestasis and imaging of the bile ducts play a major role in diagnosis. If tests show elevated alkaline phosphatase and GGT, and the clinical picture suggests bile duct involvement, the physician may prescribe specialized imaging methods. They help detect strictures, dilatations and characteristic duct changes. In some cases, other causes of sclerosing cholangitis must be excluded, including tumor-related, infectious, drug-induced and immune conditions.

Primary sclerosing cholangitis requires especially careful follow-up because it is associated not only with the risk of cirrhosis, but also with an increased risk of certain tumors of the bile ducts and intestine. Therefore, patient management includes liver monitoring, assessment of bile ducts, bowel surveillance in associated inflammatory bowel disease and timely detection of complications.

Why autoimmune liver diseases are difficult to recognize

Autoimmune liver diseases often do not have one clear symptom that immediately distinguishes them from other conditions. Fatigue, itching, abdominal discomfort, reduced appetite, joint pain or mild elevation of liver enzymes may occur in different diseases. Therefore, the patient may not understand for a long time that the problem is related specifically to the liver.

In addition, autoimmune liver diseases may coexist with other autoimmune conditions. Some patients have thyroid disease, rheumatological conditions, inflammatory bowel disease, type 1 diabetes, celiac disease or other immune disorders. Such combinations may help the physician suspect an autoimmune process, but they also make diagnosis more complex because symptoms may overlap.

Another difficulty is that laboratory patterns may differ. In autoimmune hepatitis, ALT and AST elevation usually predominates, meaning signs of liver cell injury. In cholestatic diseases, alkaline phosphatase and GGT are more often elevated. But in real clinical practice, patterns may be mixed. Sometimes a patient has signs of an overlap syndrome, when features of autoimmune hepatitis are combined with signs of bile duct involvement.

Which tests help in diagnosis

Diagnosis of autoimmune liver diseases requires a systematic approach. A single positive antibody test does not always mean disease, and one normal marker does not always completely exclude the problem. The physician evaluates the entire set of findings.

Several groups of investigations are usually used:

1. Liver tests.
   ALT, AST, bilirubin, GGT and alkaline phosphatase help determine whether liver cell injury or impaired bile flow predominates.
2. Immunological markers.
   Autoantibodies can help diagnose autoimmune hepatitis, primary biliary cholangitis and other conditions. However, their meaning is always assessed in the context of the clinical picture.
3. Immunoglobulins.
   Elevated IgG is more often associated with autoimmune hepatitis, while elevated IgM may occur in primary biliary cholangitis.
4. Virological tests.
   It is important to exclude hepatitis B, C, D and other infections, because viral diseases may cause similar changes in liver enzymes.
5. Ultrasound of the liver and bile ducts.
   This helps assess liver structure, bile duct dilatation, signs of cirrhosis, portal hypertension or focal changes.
6. Elastography.
   This is used to assess fibrosis and monitor liver condition over time.
7. MRI of the bile ducts.
   This may be important when primary sclerosing cholangitis or other causes of impaired bile flow are suspected.
8. Liver biopsy.
   Sometimes it is required to confirm the diagnosis, assess inflammatory activity, determine the degree of fibrosis and distinguish overlap forms of disease.

The goal of diagnosis is not simply to find autoantibodies, but to understand the mechanism of liver damage, the activity of the process and the risk of progression.

Treatment: why immune inflammation must be controlled

Treatment of autoimmune liver diseases depends on the specific diagnosis. In autoimmune hepatitis, the main goal is to suppress inflammation that destroys liver cells. In primary biliary cholangitis, it is important to reduce cholestasis and bile duct injury. In primary sclerosing cholangitis, treatment is more complex because the disease is connected with chronic changes in the bile ducts and requires monitoring for complications.

The general goals of treatment can be described as follows:

1. Reduce inflammatory activity.
   This is especially important in autoimmune hepatitis, where uncontrolled inflammation may quickly lead to fibrosis.
2. Slow fibrosis progression.
   The less chronic injury persists, the lower the risk of cirrhosis.
3. Preserve liver function.
   It is important not only to improve tests, but also to prevent decline in the synthetic and metabolic functions of the organ.
4. Control symptoms.
   In cholestatic diseases, treatment of itching, deficiencies and problems related to impaired bile flow is especially important.
5. Prevent complications.
   In advanced fibrosis or cirrhosis, monitoring for portal hypertension and liver cancer risk is necessary.
6. Assess response to therapy.
   If markers do not improve, the physician reassesses the diagnosis, treatment adherence, drug doses and possible additional causes of liver damage.

Treatment must be long-term and controlled. Stopping medications independently in autoimmune hepatitis may lead to a flare of inflammation. On the other hand, excessive immunosuppression also carries risks. Therefore, therapy requires a balance between disease suppression and patient safety.

Why follow-up is needed even with good well-being

In autoimmune liver diseases, how the patient feels does not always reflect disease activity. A patient may feel well but have active inflammation in blood tests. Or, conversely, pronounced fatigue may persist even when biochemical markers improve. Therefore, the assessment of disease status is not based only on complaints.

Regular follow-up usually includes liver tests, immunological markers when indicated, fibrosis assessment, ultrasound, elastography and monitoring of possible treatment adverse effects. In cirrhosis, surveillance for complications is added, including portal hypertension and the risk of tumor changes.

Disease duration is especially important. Even if inflammation is well controlled, the patient may need many years of follow-up because autoimmune liver diseases tend to have a chronic course. The physician’s goal is not only to improve laboratory markers, but also to maintain stable condition over a long period of time.

Why late diagnosis is dangerous

If an autoimmune liver disease remains undiagnosed for a long time, chronic inflammation may lead to advanced fibrosis and cirrhosis. At the stage of cirrhosis, treatment becomes more difficult because it is necessary to control not only activity of the underlying disease, but also the consequences of structural liver remodeling. The patient may develop portal hypertension, ascites, low platelet count, clotting disorders, low albumin and other signs of worsening liver function.

Late detection may also limit treatment possibilities. In the early stages, control of inflammation can significantly slow progression. In advanced disease, part of the damage may become irreversible. Therefore, it is important to pay attention to persistent elevation of liver enzymes, signs of cholestasis, itching, unexplained fatigue, coexistence with other autoimmune diseases and family history.

In some diseases, especially primary sclerosing cholangitis, late diagnosis may be associated with a higher risk of bile duct complications. Therefore, diagnosis must be not only laboratory-based, but also instrumental when relevant signs are present.

Main conclusion

Autoimmune liver diseases show that the liver can be damaged not only by viruses, alcohol or metabolic disorders. Sometimes the immune system itself becomes the cause of chronic inflammation. Autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis have different mechanisms, but all of them can lead to fibrosis, cirrhosis and reduced liver function if not controlled in time.

The main difficulty of these diseases is that they may remain hidden for a long time or present with nonspecific symptoms. Therefore, laboratory diagnostics, autoimmune markers, assessment of bile ducts, elastography, exclusion of viral and drug-induced causes of liver injury and sometimes biopsy are important. The earlier the diagnosis is established and correct treatment is started, the greater the possibility of preserving liver structure and function.

Modern management of autoimmune liver diseases is based on long-term follow-up, control of inflammation, fibrosis assessment and prevention of complications. This is not a one-time diagnosis, but a consistent strategy. With the correct approach, many patients can maintain stable condition for a long time, but this requires not ignoring changes in laboratory tests and not relying only on how they feel.